Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by Cancer and Leukemia Group B.
Recruitment status was  Active, not recruiting
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Cancer and Leukemia Group B Identifier:
First received: June 6, 2001
Last updated: April 10, 2012
Last verified: April 2011

June 6, 2001
April 10, 2012
May 2001
July 2007   (final data collection date for primary outcome measure)
Toxicity [ Time Frame: 90 days and 1 year post tx ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00016913 on Archive Site
  • Time to prostate-specific antigen failure [ Time Frame: Wk 1 ea chemotx cycle & in follow up ] [ Designated as safety issue: No ]
    Follow up is q 3 mon for 2 yrs then q 6 mon for 4 years
  • Progression-free survival [ Time Frame: registration to progression ] [ Designated as safety issue: No ]
    progression includes PSA, local or distant ds, or death
  • Overall survival [ Time Frame: 6 years post treatment ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Phase II Study Of Neo-Adjuvant Paclitaxel, Estramustine And Carboplatin (TEC) Plus Androgen Ablation Prior To Radiation Therapy In Patients With Poor Prognosis Localized Prostate Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin or leuprolide may stop the adrenal glands from producing androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, hormone therapy, and radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying giving chemotherapy together with hormone therapy and radiation therapy in treating patients with locally advanced prostate cancer.


  • Determine the feasibility and safety of paclitaxel, estramustine, carboplatin, and androgen ablation followed by radiotherapy in patients with poor-prognosis locally advanced prostate cancer.
  • Determine the progression-free survival and time to prostate specific antigen failure in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive paclitaxel IV over 1 hour once weekly; oral estramustine three times a day, five days a week; and carboplatin IV over 1 hour once monthly. Treatment repeats every 4 weeks for 4 courses.

Patients also receive gonadotropin-releasing hormonal therapy comprising either goserelin subcutaneously or leuprolide intramuscularly once monthly. Treatment repeats every 4 weeks for 6 courses.

After the completion of chemotherapy, patients undergo radiotherapy once daily on weeks 17-24.

Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years and then every 6 months for 4 years.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 1.5 years.

Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
  • Drug: carboplatin
    AUC=6 week one of each 4 week cycle
  • Drug: estramustine
    2 tablets tid PO 5 of 7 days per week each 4 week cycle
  • Drug: paclitaxel
    80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle
  • Radiation: radiation therapy
    77.4 Gy in 1.8 Gy fractions
  • Drug: leuprolide
    7.5 mg IM injection once every 4 weeks for 6 months
    Other Name: GnRH
Experimental: Neo-Adj ChemoTx + ablation prior to RT
Treatment with chemotherapy plus androgen ablation prior to radiation treatment for poor prognosis localized prostate cancer
  • Drug: carboplatin
  • Drug: estramustine
  • Drug: paclitaxel
  • Radiation: radiation therapy
  • Drug: leuprolide
Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E; Cancer Leukemia Group B. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Cancer. 2008 Dec 1;113(11):3137-45. doi: 10.1002/cncr.23910.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
January 2013
July 2007   (final data collection date for primary outcome measure)


  • Histologically confirmed adenocarcinoma of the prostate with one of the following prognostic factors:

    • Tx N0, baseline prostate specific antigen (PSA) greater than 20 ng/mL, and Gleason score at least 7
    • T3b-4 N0, any baseline PSA, and any Gleason score
  • No pelvic lymph node disease requiring pelvic radiotherapy
  • No metastatic disease by bone scan, CT scan, or MRI



  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • Granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • SGOT no greater than 1.5 times ULN


  • Creatinine no greater than 1.5 times ULN


  • No significant cardiovascular disease
  • No New York Heart Association class III or IV congestive heart failure
  • No active angina pectoris
  • No myocardial infarction within the past 6 months
  • No history of hemorrhagic or thrombotic cerebral vascular accident
  • No deep vein thrombosis within the past 6 months


  • No pulmonary embolism within the past 6 months


  • Fertile patients must use effective contraception


Biologic therapy:

  • No prior immunotherapy for prostate cancer
  • No concurrent routine filgrastim (G-CSF) or sargramostim (GM-CSF)


  • No prior chemotherapy for prostate cancer
  • No other concurrent anticancer chemotherapy

Endocrine therapy:

  • No more than 6 weeks of prior androgen deprivation therapy
  • No other concurrent anticancer hormonal therapy except steroids for adrenal failure and/or hormones for nondisease-related conditions (e.g., insulin for diabetes)


  • See Disease Characteristics
  • No prior radiotherapy for prostate cancer
  • No other concurrent anticancer radiotherapy


  • At least 4 weeks since prior major surgery


  • No prior alternative therapy (e.g., PC-SPES) for prostate cancer
  • No concurrent alternative medicine (e.g., PC-SPES or saw palmetto) or large quantities of vitamins
  • No other concurrent anticancer therapy
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
CDR0000068632, U10CA031946, CALGB-99811
Cancer and Leukemia Group B
Cancer and Leukemia Group B
National Cancer Institute (NCI)
Study Chair: William K. Kelly, DO Yale University
Cancer and Leukemia Group B
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP